Hospira Expands Recall of Propofol and Liposyn

Hospira is voluntarily expanding its recall of its Propofol Injectable Emulsion 1% and Liposyn products, including Liposyn II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20% and Liposyn III 30%, due to particulate matter found in some of the containers, according to an alert from the U.S. Food and Drug Administration.

Advertisement

Staff

The affected lot numbers are:

  • Propofol — lot numbers beginning with 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.   
  • Liposyn — lot numbers beginning with 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.

The affected lots of propofol were distributed between March 2008 and April 2010. The affected lots of Liposyn were distributed between Dec. 2008 and April 2010.

Read the FDA’s alert about the Hospira recall.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.